Amgen (AMGN)
(Delayed Data from NSDQ)
$321.91 USD
+0.12 (0.04%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $321.92 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$321.91 USD
+0.12 (0.04%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $321.92 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Zacks News
Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Amgen (AMGN) concluded the recent trading session at $264.07, signifying a -0.59% move from its prior day's close.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Amgen (AMGN) Laps the Stock Market: Here's Why
by Zacks Equity Research
In the most recent trading session, Amgen (AMGN) closed at $270, indicating a +1.33% shift from the previous trading day.
Biophytis (BPTS) to Begin Phase II Obesity Study, Stock Up
by Zacks Equity Research
Biophytis (BPTS) rises in the after-market hours as it announces the launch of a new clinical development program for its investigational candidate, BIO101, to treat obesity in combination with GLP-1 drugs.
3 Top Dividend Stocks to Maximize Your Retirement Income
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Amgen (AMGN) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
Amgen (AMGN) concluded the recent trading session at $269.95, signifying a +0.69% move from its prior day's close.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Merck (MRK) Begins Phase III NSCLC Study on KRAS Candidate
by Zacks Equity Research
Merck's (MRK) phase III study will evaluate KRAS G12C inhibitor candidate MK-1084 for first-line treatment of certain patients with metastatic NSCLC.
Here's Why Amgen (AMGN) Stock is Outperforming the Industry
by Zacks Equity Research
Amgen (AMGN) expects strong sales growth of products like Tezspire, Evenity and Repatha to make up for lower revenues from oncology biosimilars and Enbrel
Amgen (AMGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
Amgen (AMGN) closed the most recent trading day at $283.04, moving -0.45% from the previous trading session.
Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Amgen (AMGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Maximize Your Retirement Portfolio with These Top-Ranked Dividend Stocks
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Precision BioSciences (DTIL) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -211.67% and 75.31%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Awaits Consumer Confidence Data
by Zacks Equity Research
Wall Street Awaits Consumer Confidence Data
Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SCHD
Wall Street Set to Post Fifth Winning Month Amid Volatility
by Zacks Equity Research
Wall Street is likely to record the fifth consecutive winning month despite volatility.
Amgen (AMGN) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
In the most recent trading session, Amgen (AMGN) closed at $280.82, indicating a +1.68% shift from the previous trading day.
3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income
by Zacks Equity Research
The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?
ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study
by Zacks Equity Research
ACELYRIN (SLRN) posts positive proof-of-concept data from a phase I/II study evaluating its pipeline candidate, lonigutamab, for treating thyroid eye disease. Stock gains.
Amgen (AMGN) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Amgen (AMGN) stood at $271.73, denoting a +0.31% change from the preceding trading day.
Why Amgen (AMGN) Outpaced the Stock Market Today
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $270.90, marking a +0.76% move from the previous day.